Role of ICAM-1 in chronic ethanol consumption-enhanced liver injury after gut ischemia-reperfusion in rats

YOSHINORI HORIE,1 YOSHIYUKI YAMAGISHI,1 SHINZO KATO,1 MIKIO KAJIHARA,1 HIRONAO TAMAI,1 D. NEIL GRANGER,2 AND HIROMASA ISHII1

1Department of Internal Medicine, School of Medicine, Keio University, Tokyo 160 8582, Japan; and 2Department of Physiology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71110

Received 13 March 2002; accepted in final form 16 April 2002

Horie, Yoshinori, Yoshiyuki Yamagishi, Shinzo Kato, Mikio Kajihara, Hironao Tamai, D. Neil Granger, and Hiromasa Ishii. Role of ICAM-1 in chronic ethanol consumption-enhanced liver injury after gut ischemia-reperfusion in rats. Am J Physiol Gastrointest Liver Physiol 283: G537–G543, 2002. First published April 24, 2002; 10.1152/ajpgi.00098.2002.—Intercellular adhesion molecule-1 (ICAM-1) has been implicated in the hepatic microvascular dysfunction elicited by gut ischemia-reperfusion (I/R). Although the effects of chronic ethanol (EtOH) consumption on the liver are well known, it remains unclear whether this condition renders the hepatic microcirculation more vulnerable to the deleterious effects of gut and/or hepatic I/R. The objectives of this study were to determine whether chronic EtOH consumption alters the severity of gut I/R-induced hepatic microvascular dysfunction and hepatocellular injury and to determine whether ICAM-1 contributes to this response. Male Wistar rats, pair fed for 6 wk a liquid diet containing EtOH or an isocaloric control diet, were exposed to gut I/R. Intravital video microscopy was used to monitor leukocyte recruitment in the hepatic microcirculation, the number of nonperfused sinusoids (NPS), and plasma concentrations of endotoxin and tumor necrosis factor-α. Plasma alanine aminotransferase (ALT) levels were measured 6 h after the onset of reperfusion. In control rats, gut I/R elicited increases in the number of stationary leukocytes, NPS, and plasma endotoxin, tumor necrosis factor-α, and ALT. In EtOH-fed rats, the gut I/R-induced increases in NPS and leukostasis were blunted in the midzonal region, while exaggerated leukostasis was noted in the pericentral region and terminal hepatic venules. Chronic EtOH consumption also enhanced the gut I/R-induced increase in plasma endotoxin and ALT. The exaggerated responses to gut I/R normally seen in EtOH-fed rats were largely prevented by pretreatment with a blocking anti-ICAM-1 monoclonal antibody. In conclusion, these results suggest that chronic EtOH consumption enhances gut I/R-induced hepatic microvascular dysfunction and hepatocellular injury in the pericentral region and terminal hepatic venules via an enhanced hepatic expression of ICAM-1.

leukocyte adhesion; adhesion molecule; endotoxin; microcirculation; cytokine

A LARGE BODY OF EVIDENCE implicates leukocytes as mediators of the microvascular dysfunction and tissue injury associated with reperfusion of ischemic organs. Several experimental strategies have been used to demonstrate the contribution of leukocytes to ischemia-reperfusion (I/R) injury, including polyclonal antibodies that render animals leukopenic (17, 19, 28), adhesion molecule-specific monoclonal antibodies (10, 17, 22, 31), and adhesion molecule-deficient mice (16, 20). The effectiveness of adhesion molecule-specific monoclonal antibodies (MAbs) and adhesion molecule deficiency in attenuating I/R-induced tissue injury has led to the widely held view that leukocyte-endothelial cell adhesion is a rate-determining step in the pathogenesis of this injury process.

Recent studies (11) have implicated intercellular adhesion molecule-1 (ICAM-1), a ligand for the β2-integrins (CD11/CD18) on leukocytes, as a key modulator of leukocyte-endothelial cell adhesion. ICAM-1 is expressed at low levels on resting vascular endothelium, and its expression is markedly upregulated by certain proinflammatory agents such as cytokines [e.g., tumor necrosis factor (TNF)-α] and endotoxin (8, 9). Previous reports (13, 16, 17) described an attenuated leukocyte recruitment and hepatocellular dysfunction induced by gut I/R in rats receiving an adhesion molecule-specific MAb directed against CD11/CD18 or ICAM-1 as well as in adhesion molecule (CD11/CD18 or ICAM-1)-deficient mice. These observations implicate a key role for ICAM-1 in gut I/R-induced hepatic microvascular dysfunction and the accompanying hepatic (hepatocellular) injury.

Clinically, long-term alcohol consumption has been noted to significantly reduce the incidence of coronary artery disease (25). In the liver, however, chronic alcohol consumption often results in fat deposition (fatty liver) and organ failure, particularly when these fat-laden tissues are used as donor organs in liver transplantation. This important clinical problem has drawn attention to the relationship between ethanol (EtOH) consumption and reperfusion injury in the liver. Gut I/R and chronic consumption of EtOH are known to cause liver injury via mechanisms that involve oxida-
tive stress and microcirculatory disturbances, including leukocyte sequestration and sinusoidal malperfusion (18). Gut I/R is known to elevate plasma endotoxin levels (13), whereas chronic EtOH consumption has been reported to enhance the hepatic microcirculatory dysfunction and hepatocellular injury induced by endotoxin (1, 15, 26). On the basis of these observations, one might expect that chronic EtOH consumption would lead to an exaggerated liver injury response to gut I/R. This possibility is supported by reports describing enhanced I/R-induced hepatotoxicity (an increase in blood levels of liver enzymes) after EtOH consumption in a perfused liver model (38) as well as neutralophil accumulation in the gut wall after intestinal I/R (32). By contrast, an attenuation of I/R-induced cerebral vascular injury after pretreatment with EtOH has also been described (27). Furthermore, we recently reported that low-dose acute EtOH consumption affords protection against gut I/R-induced hepatic microvascular dysfunction in the midzonal region and subsequent hepatocellular injury, whereas high-dose EtOH enhances the hepatic leukosequestration, impaired sinusoidal perfusion, and hepatocellular injury caused by gut I/R (37).

Although the available literature suggests that the acute effects of EtOH on gut I/R-induced liver injury are deleterious, the responses of the liver to gut I/R in the face of chronic EtOH consumption remain unclear. Furthermore, the overall importance of leukocyte recruitment in the liver injury response to gut I/R in animals subjected to chronic EtOH consumption is not readily apparent from the literature. Hence, the overall objectives of this study were 1) to determine whether chronic EtOH consumption alters the severity of the hepatic microvascular dysfunction and hepatocellular injury induced by gut I/R and 2) to assess the contribution of ICAM-1-mediated leukocyte recruitment to this injury response.

MATERIALS AND METHODS

Animals. Male Wistar rats weighing ~150 g were pair fed for 6 wk a liquid diet containing EtOH that provided 36% of the total dietary calories or an isocaloric control diet according to the method of Lieber and DeCarli (23). All rats were fasted for 18 h before the experiment. All experiments were performed according to the criteria outlined by the US National Research Council.

Intravital microscopy. The rats were anesthetized with pentobarbital sodium (35 mg/kg ip). The left carotid artery was cannulated, and the catheter was placed at the aortic arch for blood pressure monitoring. The left jugular vein was also cannulated for drug administration. After laparotomy, a lobe of the liver was observed with an inverted intravital microscope (model TMD-2S, Diaphot, Nikon, Tokyo, Japan) assisted by a silicone-intensified target camera (model C-2400-08, Hamamatsu Photonicus, Shizuoka, Japan). The liver was placed on an adjustable Plexiglas microscope stage with a nonfluorescent coverslip that allowed for observation of a 2-cm² segment of tissue. The liver was carefully placed to minimize the influence of respiratory movements. The liver surface was moistened and covered with cotton gauze soaked with saline. Images of the microcirculation were observed from the surface of the liver through a ×20 fluorescent objective. The microfluorographs were recorded on videotape using a videocassette recorder (model S VHS-HQ, Victor).

Liver enzyme, endotoxin, and TNF assays. At 60 min after the onset of reperfusion, the rats were sacrificed. Blood (plasma) samples for measurement of endotoxin and TNF-α levels were collected from the inferior vena cava at a point proximal to the hepatic vein at 1 h after the onset of reperfusion. For measurement of endotoxin levels, blood samples were also collected from the portal vein. Samples for plasma alanine aminotransferase (ALT) measurement were obtained at 6 h after the onset of reperfusion. Plasma ALT activity was determined by conventional ultraviolet methods, as previously described (14). Plasma TNF-α concentration was determined in a microtiter plate using a TNF-α immunoassay kit (BioSource International, Camarillo, CA) based on enzyme-linked immunosorbent assay. According to our previous report (33), plasma endotoxin levels were measured by en-
dospecy (an endotoxin-specific chromogeic Limulus reagent; Seikagaku, Tokyo, Japan) using an automated kinetic assay for endotoxin (35).

Statistics. The data were analyzed using standard statistical analyses, i.e., ANOVA and Scheffé’s (post hoc) test. Values are means ± SE of five rats per group. Statistical significance was set at $P < 0.05$.

RESULTS

Figure 1 illustrates the effects of anti-ICAM-1 MAb treatment on gut I/R-induced leukostasis in sinusoids of the midzonal and pericentral regions and the terminal hepatic venule (THV; Fig. 1A) of the liver lobule and the entire liver lobule (sinusoids + THV; Fig. 1B) in the presence or absence of chronic EtOH consumption. In control rats, gut I/R elicited increases in the number of stationary leukocytes in hepatic sinusoids and THV. In EtOH-fed rats, the gut I/R-induced leukostasis was blunted in the periportal and midzonal regions (12.6 ± 0.6 and 8.0 ± 0.8 per field in control and EtOH-fed rats, respectively), while exaggerated leukostasis was noted in the pericentral region (4.3 ± 0.8 and 7.1 ± 0.8 per field in control and EtOH-fed rats, respectively) and THV (4.0 ± 0.6 and 13.3 ± 0.7 per field in control and EtOH-fed rats, respectively). Although the leukostasis elicited by gut I/R in control rats was attenuated by pretreatment with a blocking anti-ICAM-1 MAb, the exaggerated leukostasis in EtOH-fed rats was largely prevented by pretreatment with the blocking anti-ICAM-1 MAb (5.0 ± 0.7 and 5.5 ± 0.7 per field in pericentral region and THV, respectively).

Figure 2 summarizes the effects of anti-ICAM-1 MAb treatment on the gut I/R-induced increase in the percentage of nonperfused sinusoids (NPS) in the presence or absence of chronic EtOH consumption. In control rats, gut I/R elicited a significant increase in NPS. However, this response was blunted in EtOH-fed rats (22.5 ± 0.8 and 11.6 ± 1.1% for control and EtOH-fed rats, respectively, $P < 0.01$). Although the gut I/R-induced increase in NPS was attenuated by pretreatment with the blocking anti-ICAM-1 MAb in control rats, it did not affect the response in EtOH-fed rats.

Figure 3 shows the effects of anti-ICAM-1 MAb treatment on plasma ALT levels after gut I/R in the
presence or absence of chronic EtOH consumption. In control rats, gut I/R led to an elevated plasma ALT level. Chronic EtOH consumption enhanced the gut I/R-induced increase in plasma ALT levels (115 ± 12 and 263 ± 48 IU/l for control and EtOH-fed rats, respectively). The increase in plasma ALT levels elicited by gut I/R in control and EtOH-fed rats was significantly attenuated by pretreatment with the blocking anti-ICAM-1 MAb.

Table 1 shows the effects of anti-ICAM-1 MAb treatment on plasma systemic and portal endotoxin levels after gut I/R in the presence or absence of chronic EtOH consumption. Gut I/R caused a slight elevation of plasma systemic and portal endotoxin levels in control rats, whereas chronic EtOH consumption enhanced the gut I/R-induced increase in plasma systemic and portal endotoxin levels (26.3 ± 11.3, 93.2 ± 21.4, 47.0 ± 8.5, and 104.0 ± 10.0 pg/ml for systemic control, systemic EtOH, portal control, and portal EtOH, respectively). The exaggerated elevation of plasma systemic endotoxin levels in EtOH-fed rats was largely prevented by pretreatment with the anti-ICAM-1 MAb (25.7 ± 7.9 pg endotoxin/ml), whereas pretreatment with the anti-ICAM-1 MAb caused a small reduction of the exaggerated increase in plasma portal endotoxin levels in EtOH-fed rats (there was no significant reduction but no significant difference between that in control and EtOH-fed rats after pretreatment with the anti-ICAM-1 MAb).

Figure 4 summarizes the effects of anti-ICAM-1 MAb treatment on the gut I/R-induced increase in plasma TNF-α levels in the presence or absence of chronic EtOH consumption. In control rats, gut I/R elicited a significant increase in plasma TNF-α levels. Although chronic EtOH consumption did not affect gut I/R-induced increases in plasma TNF-α levels, anti-ICAM-1 MAb treatment reduced plasma TNF-α in control and EtOH-fed rats.

**DISCUSSION**

Several novel aspects of this study extend the existing body of knowledge on the hepatic microvascular and parenchymal cell responses to gut I/R in rats.
chronically fed EtOH. Our study represents the first systematic evaluation of the effects of gut I/R on the liver of rats chronically fed EtOH. This work also provides suggestive evidence with a blocking anti-ICAM-1 MAb that leukocyte-endothelial cell adhesion is an important determinant of the exaggerated microvascular dysfunction and tissue injury observed after gut I/R in the liver of rats chronically fed EtOH.

Reperfusion of the ischemic intestine in control rats results in accumulation of adherent leukocytes in sinusoids and THV, reduction in the number of perfused sinusoids, and release of liver enzymes (ALT) into the bloodstream. In control rats, the gut I/R-induced leukostasis in the pericentral region and THV was not noted after pretreatment with the anti-ICAM-1 MAb. This pretreatment also attenuated the gut I/R-induced increase in plasma ALT and TNF-α levels. Overall, the findings are consistent with our previous studies (13, 16, 17). An interesting finding in the present study is that the gut I/R-induced increase in plasma endotoxin level was not seen in control rats after pretreatment with the anti-ICAM-1 MAb. Gut I/R was reported to result in elevated plasma endotoxin, which appears to be derived from the gut. The anti-ICAM-1 MAb has been reported to blunt mesenteric I/R injury (22). Taken together, these results and evidence in the literature suggest that the anti-ICAM-1 MAb reduces blood endotoxin levels by protecting the intestinal mucosal barrier from I/R injury, thereby preventing the subsequent hepatic microvascular dysfunction and hepatocellular injury. Because endotoxin is a potent stimulant for ICAM-1 expression (2, 9), the reduction of plasma endotoxin levels by the anti-ICAM-1 MAb might result in a blunted expression of ICAM-1 in the liver.

Another interesting finding in the present study is that chronic EtOH consumption exaggerated the gut I/R-induced leukostasis in the liver and the subsequent hepatic microvascular dysfunction (ALT elevation). A growing body of literature is based on the use of animals chronically fed EtOH to study the pathogenesis of alcoholic liver injury per se as well as the influence of chronic EtOH feeding on stimulus-induced liver inflammation (1, 5, 7, 15, 26). For example, chronic EtOH consumption has been reported to enhance the hepatic microcirculatory disturbances and liver injury induced by endotoxin (1, 15, 26). The findings of the present study support the possibility that elevated plasma levels of endotoxin also contribute to the exaggerated inflammatory and tissue injury responses seen in the liver after gut I/R in rats chronically fed EtOH. Because endotoxin levels are also elevated in otherwise normal rats (i.e., those not fed EtOH) after gut I/R, it is also possible that endotoxin contributes to the pathogenesis of gut I/R-induced liver injury. In the present study, the portal endotoxin level was higher in rats chronically fed EtOH than in control rats. This result suggests that intestinal mucosal permeability was increased in EtOH-fed rats after gut I/R. However, the systemic endotoxin level was much lower than the portal endotoxin level in control rats, in contrast to no significant difference between systemic and portal endotoxin levels in EtOH-fed rats after gut I/R. This result suggests that clearance of endotoxin in EtOH-fed rats was impaired. Thus an increase in intestinal mucosal permeability and a reduction of endotoxin clearance in EtOH-fed rats can be involved in the enhancement of plasma}

![Diagram](http://ajpgi.physiology.org/extrafig.png)
endotoxin levels. Indeed, pretreatment with the anti-ICAM-1 MAb caused a small reduction of the exaggerated increase in plasma portal endotoxin levels in EtOH-fed rats (there was no significant reduction but no significant difference between that in control and EtOH-fed rats after pretreatment with the anti-ICAM-1 MAb).

Although chronic EtOH consumption enhanced the gut I/R-induced increase in plasma endotoxin levels, it did not affect the gut I/R-induced increase in plasma TNF-α levels. However, chronic EtOH consumption enhanced the gut I/R-induced increase in plasma ALT activities with a parallel increase in leukostasis in the liver. It is similar to the findings in our acute EtOH model (37) that pretreatment with high-dose EtOH administration markedly enhanced the gut I/R-induced increase in plasma endothelin levels but not the gut I/R-induced increase in plasma TNF-α levels. These results suggest that leukostasis per se or leukocyte-derived oxidants may play a more important role in the gut I/R-induced liver (hepatocellular) injury than cytokines. Another likely interpretation is that cytokines other than TNF-α are involved in the enhanced responses after gut I/R in rats chronically fed EtOH.

The expression of ICAM-1 has been shown in a variety of liver diseases (2, 24). Increased ICAM-1 expression has been observed on hepatocytes and on endothelial cells lining hepatic sinusoids in several inflammatory liver diseases. The role of ICAM-1 in alcoholic liver injury has recently received attention (2, 21, 36). Our findings with an anti-ICAM-1 MAb implicate this endothelial cell adhesion molecule in the mechanism(s) responsible for the exaggerated hepatic inflammatory and injury responses to gut I/R that are seen in rats chronically fed EtOH. Pretreatment with the blocking anti-ICAM-1 MAB resulted in blunted inflammatory and microvascular responses in the liver as well as an attenuated increase in plasma ALT levels after gut I/R compared with control rats. These results suggest that ICAM-1 expressed in the liver contributes to the exaggerated responses to gut I/R in rats chronically fed EtOH. However, it remains unclear whether it is the ICAM-1 that is constitutively expressed in the liver or the newly expressed ICAM-1 (possibly in response to endotoxin) that mediates the responses noted in our study. ICAM-1 expression in the liver was reported to be enhanced in patients with alcoholic hepatitis (6). It has also been reported that soluble circulating ICAM-1 and E-selectin levels are higher in alcoholics, whereas serum vascular cell adhesion molecule-1 levels are similar to those in nonalcoholics (29).

Because serum levels of endothelial cell adhesion molecules may reflect their expression on endothelial cells, the evidence from clinical studies supports the possibility that ICAM-1 expression is elevated in the livers of animals chronically fed EtOH. A role for ICAM-1 is further supported by reports describing that chronic EtOH consumption enhances endotoxin-induced leukostasis in the liver via an increased expression of LFA-1 and CD18 on leukocytes, which is a counterligand for ICAM-1 (4, 26). This enhanced expression of LFA-1 and CD18 may contribute to the enhancement of gut I/R-induced leukostasis in THV of rats chronically fed EtOH.

ICAM-1 expression can be induced by cytokines such as TNF-α (8, 9, 12). In the present study, plasma TNF-α levels were not different between control rats and rats chronically fed EtOH after gut I/R, whereas plasma TNF-α levels in rats chronically fed EtOH were almost twice the levels in control animals. This small increase in plasma TNF-α concentration may contribute to the enhanced expression of ICAM-1 in THV of rats chronically fed EtOH. However, most studies of TNF-α-induced expression of ICAM-1 have employed a single injection of a high dose of TNF-α. It remains unclear whether the small elevation in plasma TNF-α detected in our studies led to a functional increase in ICAM-1 expression in the liver. Reactive oxygen species are believed to rapidly increase the ability of endothelial ICAM-1 to bind neutrophils without detectable upregulation (30). Because it is widely accepted that reactive oxygen species play an important role in hepatic reperfusion injury and alcoholic liver disease (18, 36), it is possible that chronic EtOH consumption-enhanced enhancement of free radical formation after gut I/R may contribute to the gut I/R-induced leukostasis in the liver by activating constitutively expressed ICAM-1.

This study was supported by grants from the Japanese Ministry of Education and Science. D. N. Granger is supported by National Heart, Lung, and Blood Institute Grant HL-26441.

REFERENCES


10. Farhood A, McGuire GM, Manning AM, Miyasaka M, Smith CW, and Jaeschke H. Intercellular adhesion molecule 1


